Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products:
Minimal Manipulation and Homologous Use
FDA Issues Extension period to May 31, 2021 for minimal manipulation products.
Maximum Signaling for Maximum Regeneration
RichSource Announces Non-Invasive Breakthrough Product RICHGEN
News On Fallen Brands
FDA Bans Culture Expansion of Extracellular Vesicles
FDA Issues Kimera Labs Warning
Kimera Labs Sued by Age Bio Marq Lab
Dr. Selinger vs. Kimera Labs Inc.
FDA Issues Form 483 on Invitrx
Concerning Invitrx Inspection Report
Predictive Biotech Falls
Predictive Biotech FDA Warning
